目的 分析苏州九龙医院2014-2018年口服抗高血压药物的使用情况及变化趋势，为临床合理用药及药品管理提供依据。方法 运用描述性统计分析方法，对2014-2018年苏州九龙医院口服抗高血压药物的品种结构、销售金额、用药频度（DDDs）、限定日费用（DDC）和排序比（B/A）等进行回顾性统计分析。结果 口服抗高血压药物共29个通用名、42个品规，均为苏州市医保品种，其中属于2018版国家基本药物目录的共12个通用名、17个品规；不同年份口服抗高血压药物的品种略有差异；5大类品种年度使用金额及基药占比均呈先增后降趋势，不同品种年度金额占比较为稳定，单片复方制剂占比最高，ACEI占比最低；不同年度使用金额与频率排名前10位的品种较为集中；不同年度DDC最高的为2017年，最低的为2018年；B/A<1的品规数占比最高。结论 2014-2018年苏州九龙医院口服抗高血压药物及基本药物品种的使用金额、使用频率的排序与占比结构较稳定，随着药品新标降价政策的实施，使用金额与日均费用在2018年均有明显的下降；不足之处在于价位较高药品的使用占比较高，临床药师应协助临床医师选择价格适中，性价比相对高的药物，更好的减轻患者的经济负担。

Objective To analyze the use and trend of oral antihypertensive drugs in Suzhou Kowloon Hospital from 2014 to 2018, and provide evidence for clinical rational drug use and drug management. Methods Descriptive statistical analysis was used to retrospectively analyze the variety structure, sales amount, DDDs, DDC, and B/A of oral antihypertensive drugs in Suzhou Kowloon Hospital from 2014 to 2018. Results There were 29 generic names and 42 product specifications for oral antihypertensive drugs, all of which belong to Suzhou medical insurance varieties. Among them, there were 12 generic names and 17 product specifications belonging to the 2018 edition of the national essential drug catalogue. Varieties of oral antihypertensive drugs varied slightly in different years. The annual use amount and the proportion of base drugs in the five major categories showed a trend of increasing first and then decreasing. The annual amount of different varieties was stable, and the single-chip compound preparation accounted for the highest proportion, and ACEI with the lowest ratio. The top 10 varieties in different annual use amount and frequency were concentrated. The highest annual DDC was in 2017, and the lowest was in 2018. B/A <1 had the highest proportion of products. Conclusion The order and proportion of sum and DDDs of medicines for hypertension in Suzhou Kowloon Hospital from 2014 to 2018 are relatively stable. Consumption sum and DDC have obviously decreased in 2018, which is related to the implementation of the new drug price reduction policy. The disadvantage lies in the high proportion of drugs used in higher prices. Clinical pharmacists should assist clinicians in choosing medicines with moderate prices and relatively high cost-effectiveness, so as to better alleviate the financial burden of patients.

R972